Le projet de l'équipe est d’identifier de nouvelles protéines et de nouveaux mécanismes impliqués dans le trafic neuronal de récepteurs, dans le but de caractériser de nouvelles cibles thérapeutiques dans le domaine de la dépression, la schizophrénie et d’autres pathologies neuronales et psychiatriques.
The goal of the research team is to analyze the roles played by environmental and genetic factors, as well as the interactions between these components, in the etiology and treatment of psychiatric disorders such as depression, anxiety and addiction. The main objective of the team is to identify cellular and molecular mechanisms underlying these pathologies which are associated with major dysfunctions of the monoamine and HPA systems and characterized by cellular plasticity alterations of different brain areas and in particular the hippocampus.
The SAN team gathers together three PIs with complementary expertise in affective neuroscience, social neuroscience, and psychiatry. Our project focuses on the functional neuroanatomy of the emotional brain. We study the brain systems of emotion detection, evaluation, and regulation, with an emphasis on how social processes (eg social inclusion) activate and regulate the emotional brain. Dysfunction of the emotional brain is central to many mental disorders and in particular to major depressive disorder (MDD).
The overall goal of our research is to decipher the mechanisms involved in major mental health problems: psychosis, depression, bipolar disorder, addiction.
The scientific core of our research program is to study the exact nature of the processing that the basal ganglia (BG) apply to cortical information with three perspectives: 1) improve our fundamental knowledge of the cerebral mechanisms of information processing; 2) better understand the pathophysiology of human diseases which are related to BG dysfunction; and 3) develop innovative treatments for neuropsychiatric refractory disorders notably by means of the deep brain stimulation (DBS) functional neurosurgery.
Our research efforts have contributed to a better identification of relevant phenotype for genetic studies, particularly on the field of bipolar disorder, schizophrenia, suicide, autism, OCD and pharmaco-genetic studies. Being principal investigator of national and international groups, she has been able to produce prominent findings such as identification in autism of the first mutations in neuroligins (NLGN-3 and NLGN-4).
Our team carries out preclinical studies to better understand psychiatric diseases and to discover innovative therapies. We develop animal models and characterize synaptic targets which play a role in neurotransmission (mostly neurotransmitter transporters). This work is also carried out in humans using genetic and anatomical approaches, specifically focusing on autism and mental retardation.
Over the past 4 years, we have been studying psychiatric disorders and addictions that are prevalent and have a high social cost. We use magnetic resonance imaging and positron emission tomography to capture brain images in severely impaired patients and to assess the effects of treatment on brain function. We are based in the Service Hospitalier Frédéric Joliot (SHFJ), Orsay. We also collaborate with a network of psychiatrists within the Paris area and collaborate on large data sets with North Europe research teams.